↓ Skip to main content

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib

Overview of attention for article published in Cancer & Metabolism, May 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib
Published in
Cancer & Metabolism, May 2014
DOI 10.1186/2049-3002-2-s1-p14
Authors

Sucheta Telang, Julie O’Neal, Gilles Tapolsky, Brian Clem, Alan Kerr, Yoannis Imbert-Ferndandez, Jason Chesney

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Student > Master 4 17%
Student > Doctoral Student 3 13%
Researcher 3 13%
Student > Bachelor 1 4%
Other 3 13%
Unknown 5 21%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 25%
Medicine and Dentistry 5 21%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Agricultural and Biological Sciences 2 8%
Chemistry 2 8%
Other 2 8%
Unknown 5 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2014.
All research outputs
#2,166,720
of 5,036,385 outputs
Outputs from Cancer & Metabolism
#23
of 57 outputs
Outputs of similar age
#63,993
of 170,174 outputs
Outputs of similar age from Cancer & Metabolism
#5
of 11 outputs
Altmetric has tracked 5,036,385 research outputs across all sources so far. This one has received more attention than most of these and is in the 55th percentile.
So far Altmetric has tracked 57 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 170,174 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.